Clinical Trial Update: Effects of Dalfampridine on Cognition in Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on dalfampridine assessing cognitive effects in multiple sclerosis across Phase 2 and Phase 3, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dalfampridine (dalfampridine)

Snippet

Sponsor: State University of New York at Buffalo | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-05-07